HIVconsvX vaccine trial for HIV begins
Scientists making COVID-19 vaccine take a big step
But the new HIVconsvX vaccine triggers the immune system’s T-cells, which are powerful and destroy pathogens. The new vaccine has been designed to target an area of the virus that rarely changes. Oxford University has said its vaccine candidate is the “best solution” to ending the AIDS epidemic. Professor Tomas Hanke, lead researcher at Oxford’s Jenner Institute, said that it took 40 years to make the vaccine. In these 40 years since the virus was detected, about 5 vaccines have been tested. Researchers say that finding protection against HIV is challenging and it is imperative that we strengthen the protective capacity of both antibodies and T-cells, the protectors of the immune system.